Lipopolysaccharide-Induced Acute Lung Injury Attenuated by Ocimum gratissimum Aqueous Extract in Mice
Die Pharmazie · 16.10.2026 · 81 (10)
DOI: 10.31083/pharmazie55633 ↗Kurz gefasst
Fachartikel in der Zeitschrift Die Pharmazie, online erschienen am 16.10.2026. Verfasst von Chen-Cheng Huang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Health Management Center, Taichung Veterans General Hospital, 407219 Taichung, Taiwan. Hauptthemen laut MEDLINE: Ocimum, Acute Lung Injury, Lipopolysaccharides, Plant Extracts. Die Arbeit nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Science and Technology Council, Ministry of Health and Welfare Research and Development Award Program.
Abstract (Originalsprache)
Background
Acute lung injury (ALI) is characterized by diffuse inflammatory damage to the alveolar–capillary barrier, and effective pharmacological options remain limited. Ocimum gratissimum contains bioactive constituents with anti-inflammatory and antioxidant properties, but its effects in experimental ALI have not been sufficiently characterized.
Methods
Male BALB/c mice were assigned to control, lipopolysaccharide (LPS), or LPS plus O. gratissimum aqueous extract (OGE) groups (n = 4 per group). OGE was administered at 2.4 mg/mL in drinking water for three days before the intratracheal LPS challenge. Since individual consumption was not recorded, 300 mg/kg/day is reported as an estimated exposure only. Mice were euthanized 30 h after LPS administration. Lung histopathology was assessed by hematoxylin and eosin staining and blinded semiquantitative injury scoring. Serum interleukin-6 (IL-6) levels were measured by enzyme-linked immunosorbent assay.
Results
LPS induced inflammatory-cell infiltration, alveolar septal thickening, and focal hemorrhage, along with increased lung-injury score and serum IL-6 levels. OGE prophylactic pretreatment reduced these histopathological abnormalities, lowered the injury score, and suppressed the LPS-associated increase in circulating IL-6. These findings are preliminary because each group contained four animals and only systemic IL-6 and histology were assessed.
Conclusion
In this preliminary prophylactic study, short-term oral pretreatment with OGE attenuated LPS-induced ALI in mice. Larger, dose-ranging studies using standardized extract, measured dosing, bronchoalveolar lavage endpoints, and post-injury administration are required before therapeutic conclusions can be drawn.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Health Management Center, Taichung Veterans General Hospital, 407219 Taichung, Taiwan.
- Division of Chest Medicine, Department of Internal Medicine, Taichung Hospital, Ministry of Health and Welfare, 40343 Taichung, Taiwan.
- Society of Adaptive Science in Taiwan, 40402 Taichung, Taiwan.
- Animal Center, Department of Medical Research, China Medical University Hospital, 40402 Taichung, Taiwan.
- Department of Biological Sciences and Technology, National University of Tainan, 700 Tainan, Taiwan.
Förderung
- National Science and Technology Council
- Ministry of Health and Welfare Research and Development Award Program
Zitieren
APA
Huang, C. C., Yang, W. T., Liu, J. Y., Chuang, Y. L., & Ye, J. C. (2026). Lipopolysaccharide-Induced Acute Lung Injury Attenuated by Ocimum gratissimum Aqueous Extract in Mice. Die Pharmazie, 81(10). https://doi.org/10.31083/pharmazie55633
Vancouver
Huang CC, Yang WT, Liu JY, Chuang YL, Ye JC. Lipopolysaccharide-Induced Acute Lung Injury Attenuated by Ocimum gratissimum Aqueous Extract in Mice. Die Pharmazie. 2026;81(10). doi:10.31083/pharmazie55633
BibTeX
@article{Huang2026,
author = {Huang, Chen-Cheng and Yang, Wen-Ta and Liu, Jer-Yuh and Chuang, Ya-Ling and Ye, Je-Chiuan},
title = {Lipopolysaccharide-Induced Acute Lung Injury Attenuated by Ocimum gratissimum Aqueous Extract in Mice},
journal = {Die Pharmazie},
year = {2026},
volume = {81},
number = {10},
doi = {10.31083/pharmazie55633}
}
EUVIMED